A leadless pacemaker in the real-world setting:The Micra Transcatheter Pacing System Post-Approval Registry by Roberts, Paul R. et al.
Syddansk Universitet
A leadless pacemaker in the real-world setting
The Micra Transcatheter Pacing System Post-Approval Registry
Roberts, Paul R.; Clementy, Nicolas; Al Samadi, Faisal; Garweg, Christophe; Martinez-
Sande, Jose Luis; Iacopino, Saverio; Johansen, Jens Brock; Vinolas Prat, Xavier; Kowal,









Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Roberts, P. R., Clementy, N., Al Samadi, F., Garweg, C., Martinez-Sande, J. L., Iacopino, S., ... El-Chami, M. F.
(2017). A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval
Registry. Heart Rhythm, 14(9), 1375-1379. DOI: 10.1016/j.hrthm.2017.05.017
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 07. Mar. 2018
A leadless pacemaker in the real-world setting: The Micra
Transcatheter Pacing System Post-Approval Registry
Paul R. Roberts, MD,* Nicolas Clementy, MD,† Faisal Al Samadi, MD,‡ Christophe Garweg, MD,x
Jose Luis Martinez-Sande, MD,k Saverio Iacopino, MD,{ Jens Brock Johansen, MD, PhD,**
Xavier Vinolas Prat, MD,†† Robert C. Kowal, MD, PhD, FHRS,‡‡xx Didier Klug, MD, PhD,kk
Lluis Mont, MD, PhD,{{ Jan Steffel, MD, FHRS,*** Shelby Li, MD,xx Dirk Van Osch, MPH,†††
Mikhael F. El-Chami, MD, FHRS‡‡‡
From the *Southampton General Hospital–University Hospital Southampton NHS Foundation Trust,
Southampton, United Kingdom, †Centre Hospitalier Régional Universitaire de Tours-Ho^pital Trousseau,
Tours, France, ‡King Salman Heart Center–King Fahad Medical City, Riyadh, Saudia Arabia, xUniversitaire
ziekenhuizen Leuven–Campus Gasthuisberg, Leuven, Belgium, kUniversity Clinical Hospital of Santiago de
Compostela, Santiago de Compostela, Spain, {Electrophysiology Unit, Arrhythmology Department, Maria
Cecilia Hospital, Cotignola, Italy, **Department of Cardiology, Odense University Hospital, Odense,
Denmark, ††ArrhythmiaUnit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ‡‡Baylor Scott andWhite
Healthcare, Baylor University Dallas, Texas, xxMedtronic, Mounds View, Minnesota, kkCentre Hospitalier
Régional Universitaire de Lille, Lille, France, {{Hospital Universitari Clínic de Barcelona, Barcelona, Spain,
***Universitats Spital Z€urich, Z€urich, Switzerland, †††Medtronic Bakken Research Center, Maastricht, The
Netherlands, and ‡‡‡Division of Cardiology, Section of Electrophysiology, Emory University, Atlanta, Georgia.
BACKGROUND First-in-man studies of leadless pacemakers have
demonstrated high rates of implant success, and safety and efﬁcacy
objectives were achieved. Outside of the investigational setting,
there are concerns, particularly over cardiac effusion and perfora-
tion, device dislodgement, infection, telemetry, and battery issues.
OBJECTIVE The acute performance of the Micra transcatheter pace-
maker from a worldwide Post-Approval Registry is reported.
METHODS The registry is an ongoing prospective single-arm obser-
vational study designed to assess the safety and effectiveness of
Micra in the post-approval setting. The safety end point was system-
or procedure-related major complications at 30 days post implant.
We compared the major complication rate with that of the 726
patients from the investigational study. Electrical performance
was also characterized.
RESULTS The device was successfully implanted in 792 of 795 registry
patients (99.6%) by 149 implanters at 96 centers in 20 countries.
Through 30 days post implant, a total of 13 major complications
occurred in 12 patients, for a major complication rate of 1.51% (95%
conﬁdence interval, 0.78%–2.62%). Major complications included car-
diac effusion/perforation (1, 0.13%), device dislodgement (1, 0.13%),
and sepsis (1, 0.13%). After adjusting for baseline differences, the rate
of major complications in the registry trended lower than the investiga-
tional trial (odds ratio, 0.58, 95% conﬁdence interval, 0.27–1.25;
P5 .16). Early pacing capture thresholds were low and stable.
CONCLUSION Performance of the Micra transcatheter pacemaker in
a real-world setting demonstrates a high rate (99.6%) of implant
success and low rate (1.51%) of major complications through 30
days post implant. In particular, the rates of pericardial effusion,
device dislodgement, and infection were low, reinforcing the posi-
tive results seen in the investigational study.
KEYWORDS Acute performance; Leadless pacemaker; Real-world
performance
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Pocket and lead-related complications are commonly
encountered problems with traditional transvenous pace-
makers (PPM).1,2 Leadless pacemakers were designed to
minimize or eliminate these adverse events.3,4 The Micra
transcatheter pacing system (TPS) investigational device
exemption (IDE) study enrolled 745 patients.3 In this study,
the implant success rate was excellent (99.2%) and the major
complication rate through 12 months post implant was low
(4%).5 This complication rate compared favorably with the
complication rate (7.6%) seen in a prespeciﬁed transvenous
PPM historical cohort. No TPS device dislodgements or
infections were noted in these patients. In addition, device
electrical parameters (capture thresholds, sensing, and
impedance) were excellent and remained stable over 1 year
of follow-up.5 Although the results of the IDE study are
reassuring, the novelty of the technology creates concerns
over the reproducibility of these impressive initial ﬁndings.
Concerns persist over the rate of pericardial effusion and
the overall safety of Micra when implanted in the real world,
outside the investigational setting. In this study, we report the
acute performance of the Micra TPS with the initial patients
from the ongoing worldwide Post-Approval Registry.
Methods
Study design
The Micra Post-Approval Registry is a prospective,
nonrandomized, multicenter post-approval release registry
designed to further evaluate the safety and effectiveness of
the Micra TPS when used as intended, in “real-world”
practice. The protocol was approved by the ethics
committee at each of the participating centers. Adverse
events were adjudicated by a clinical events committee
comprised of independent physicians.
Patients and procedures
Patients intended to be implanted with a Micra device are
eligible for enrollment in the study. The study investigators
intend to enroll approximately 1830 patients in the study,
and enrollment is currently ongoing. All patients provided
written and informed consent prior to implant.
The Micra TPS is a single-chamber ventricular pacemaker
and is 93% smaller than a transvenous pacemaker system.
The device has similar functionality and features to
preexisting single-chamber pacemakers, including rate
adaptive pacing, remote monitoring capabilities, and
automated pacing capture threshold management, designed
to maximize battery longevity. The device is implanted
directly in the right ventricle through a femoral vein. The de-
vice is ﬁxated in the myocardium via 4 ﬂexible nitinol tines.
Enrolled patients underwent an implantation attempt and
were followed in accordance with the standard care
practices of their provider. Patient and device status are
reported at implantation/pre–hospital discharge, 30 days
post implant, and at least annually thereafter for a minimum
of 9 years.
End points
The aim of this interim analysis was to assess system- or
procedure-related major complications through 30 days
post implant. Using the same criteria as in the Micra IDE
study, major complications were deﬁned as events resulting
in death, permanent loss of device function, hospitalization,
prolonged hospitalization by 48 hours or more, or system
revision. Electrical performance at implant/pre–hospital
discharge was also characterized.
Statistical analysis
The study is a pragmatic clinical trial designed to continu-
ously monitor the performance of the newly market-
released leadless pacemaker in the real-world clinical
practice. The study primary objectives are to estimate acute
and long-term safety performance of the Micra system. No
statistical hypotheses were formulated. Study enrollment
size was calculated to yield 500Micra-implanted participants
completing 9 years’ postimplantation follow-up and to
ensure reliable estimates could be achieved for individual
complications occurring at an underlying rate of 1%.
All patients who underwent a Micra TPS implantation
attempt after written consent were included in the analysis.
Summary statistics were obtained and reported using mean
and standard deviation for continuous variables, and fre-
quencies and percentages for categorical variables. Rates of
major complications related to the Micra system or implanta-
tion procedure were calculated using the binomial method,
with 95% conﬁdence intervals calculated using the exact
method. We adopted the same deﬁnition for major complica-
tion from the IDE study to conduct the evaluations against the
IDE study. Logistic regression was performed to adjust for
potential risk factors when comparing the 2 cohorts.
Results
Patients
A total of 795 patients were enrolled from 96 centers in 20
countries, with the ﬁrst implantation procedure occurring in
July 2015. The database for the present analysis was frozen
on January 31, 2017. Patients were mostly male (62.3%);
the average age was 75.1 6 14.2 years; and 104 patients
(13.1%) had a previously implanted cardiac electronic
implantable device (Table 1), which was an exclusion crite-
rion in the IDE study. Types of previously implanted devices
were transvenous pacemaker systems (73 patients), transve-
nous implantable cardioverter-deﬁbrillators (13), epicardial
systems (11), TPSs (1), and implantable cardiac monitors
(6). In addition, 166 patients (20.9%) had 1 condition
that precluded the use of a transvenous pacing system,
including compromised venous access (72 patients), history
of or risk of infection (70), need to preserve veins for hemo-
dialysis (38), thrombosis (24), cancer (23), valvular issues/
prosthetic valve (8), and other (13). Indications for implanta-
tion were bradyarrhythmia associated with permanent or
persistent atrial tachyarrhythmia (57.7%), atrioventricular
block (14.7%), syncope (14.1%), sinus node dysfunction
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(8.0%), other indications without permanent or persistent
atrial tachyarrhythmia (3.4%), and reason not speciﬁed
(2.1%). The average follow-up duration was 1.8 6 2.9
months (range, 0–14.9 months). Micra was successfully
implanted in 792 patients (99.6%) by 149 physicians, of
which 86.6% were implanters who had not previously
implanted a Micra device. The device was implanted in the
septum for 52.1% of implants, the right ventricular apex in
39.3% of implants, the right ventricular outﬂow tract in
1.9% of implants, and in an alternate location (including
the apical-septum and low septum) in 6.3% of implants.
Most implants (77.3%) required 2 or fewer deployments.
Early safety
Through 30 days post implant, there were a total of 13 major
complications in 12 patients, for a major complication rate of
1.51% (95% conﬁdence interval [CI], 0.78%–2.62%). Major
complications are shown in Table 2. There were 6 events at
the groin puncture site (0.75%), including arteriovenous ﬁs-
tula (1 event), hematoma (2), incision site hemorrhage (1),
persistent lymphatic ﬁstula (1), and vascular pseudoaneur-
ysm (1). There was 1 pericardial effusion/perforation major
complication event, which required pericardiocentesis on
the day of implantation and resolved the same day. One local
device dislodgement (without embolization) was noted 2
days post implant; in this case, 2 tines were observed to not
be embedded in tissue and 2 tines were positioned between
the wall and papillary muscle. The same device was success-
fully repositioned at 50 days post implant, with normal pac-
ing thresholds and no further issue noted at the time of
repositioning. Sepsis was reported in 1 patient within 48
hours of the implant procedure and was successfully treated
using intravenous antibiotics, without the need for device
removal. There was no major complication related to telem-
etry or battery issues. No device embolization was observed.
Major complication criteria were not mutually exclusive,
and of the 13 major complications, 1 led to prolonged hospi-
talization, 4 led to hospitalization, 2 led to system revision,
and 1 led to death (Table 3). None of the major
complications resulted in loss of device function.
There were 22 deaths. None was related to the Micra sys-
tem, and 1 was adjudicated as related to the implantation pro-
cedure. The patient was a 96-year-old male with aortic
valvular disease who was undergoing an implantation
attempt for complete atrioventricular block and who had no
suitable access for transvenous pacing. The day after implan-
tation, the patient developed pulmonary edema and could not
be resuscitated. There was no evidence of tamponade or de-
vice migration, and the device was functioning normally at
the time of his arrest. The pulmonary edema was thought to
be related to the patient’s valvular heart disease.
Cardiac effusion/perforation events
There were 5 cardiac effusion/perforation events reported
that were adjudicated as related to the system or procedure;
none resulted in death. Three required no intervention. Two
events required drainage or pericardial puncture or both, of
which only 1 was associated with prolonged hospitalization.
Thus, of the 5 events, 1 met the major complication criteria.
In 4 of these 5 patients, the Micra was implanted at the
septum, and in 1 patient, the Micra was implanted at the
apex. Patients with cardiac effusion or perforation events
had 1 of the following risk factors: advanced age (2 of 5
patients .75 years), female gender (4 of 5), low body mass
index (1 of 5,20 kg/m2), and history of chronic obstructive
pulmonary disease (2 of 5).
Early electrical performance
Of the 701 patients with available pacing capture thresholds
at implant, 87.2% had a pacing capture threshold1.0 V and
97.0% had a pacing capture threshold 2.0 V (mean 0.6 6
0.5 V at 0.24 milliseconds). Among the patients with avail-
able pacing capture thresholds available at 3 months
(n 5 39) and 6 months (n 5 25), the average pacing capture
Table 1 Baseline Characteristics
Baseline Demographics and
Clinical Characteristics
Patients With an Implant
Attempt (N 5 795)
Age, y, mean 6 SD 75.2 6 14.2
Male gender, n (%) 495 (62.3)
LVEF, %, mean 6 SD 55.7 6 9.7
Hypertension, n (%) 454 (57.1)
Atrial ﬁbrillation, n (%) 532 (66.9)
Diabetes, n (%) 196 (24.7)
Condition that precludes the use of a
transvenous pacemaker, n (%)
166 (20.9)
Renal dysfunction, n (%) 152 (19.1)
Previously implanted CIED, n (%) 104 (13.1)
Coronary artery disease, n (%) 132 (16.6)
LBBB, n (%) 72 (9.1)
COPD, n (%) 67 (8.4)
Congestive heart failure, n (%) 46 (5.8)
CIED 5 cardiac implantable electronic device; COPD 5 coronary artery
disease; LBBB 5 left bundle branch block; LVEF 5 left ventricular ejection
fraction.
Table 2 Major Complications Through 30 Days Post Implant
Adverse Event No. (Patients, %)
Total Major Complications 13 (12, 1.51)
Deep Vein Thrombosis 1 (1, 0.13)
Events at Groin Puncture Site 6 (6, 0.75)
Arteriovenous ﬁstula 1 (1, 0.13)
Hematoma 2 (2, 0.25)
Incision site hemorrhage 1 (1, 0.13)
Persistent lymphatic ﬁstula 1 (1, 0.13)
Vascular pseudoaneurysm 1 (1, 0.13)
Cardiac Effusion/Perforation 1 (1, 0.13)
Pacing Issues 2 (2, 0.25)
Device dislodgement 1 (1, 0.13)
Device pacing issue 1 (1, 0.13)
Other 3 (3, 0.38)
Chest pain 1 (1, 0.13)
Pulmonary edema 1 (1, 0.13)
Sepsis 1 (1, 0.13)
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thresholds were 0.5 6 0.3 V and 0.6 6 0.3 V, respectively.
The average impedance was 721 6 181 U at implant, 634
6 143 U at 3 months, and 572 6 115 U at 6 months. The
mean R-wave amplitude was 11.4 6 5.3 mV at implant.
Based on 54 participants who had a minimum of 180 days
of pacing data, the preliminary estimate of median battery
longevity is 14.9 years, although 40.7% of these patients
had cumulative pacing ,5%.
Early safety versus the investigational cohort
Compared with patients from the IDE study, signiﬁcantly
fewer patients in the Post-Approval Registry had congestive
heart failure, coronary artery disease, hypertension, chronic
obstructive pulmonary disease, or atrial ﬁbrillation
(Supplemental Table 1). The mean left ventricular ejection
fraction was signiﬁcantly lower among patients in the
Post-Approval Registry, and signiﬁcantly more patients in
the registry had no venous access for a transvenous
pacemaker or had a previously implanted cardiac device, as
the latter was an exclusion criterion in the IDE study.
The major complication rate trended lower in the registry
compared with that of the IDE study (1.51% vs 2.89%; odds
ratio, 0.515, 95% CI, 0.251–1.053; P5 .0691), although this
did not reach statistical difference. After adjusting for base-
line characteristics, the major complication rate remained
lower in the registry (odds ratio, 0.58, 95% CI, 0.27–1.25;
P 5 .16). The reduction in major complications was
associated with a decrease in events that led to hospitaliza-
tion, prolonged hospitalization, or loss of device function
(Table 3). Among the 795 patients in the registry, there
were fewer cardiac effusion/perforation major complications,
compared with the 726 patients from the IDE study (1 patient,
0.13% vs 10 patients, 1.38%). The number of major
complications related to the groin puncture site was similar
in both studies (6 events, 0.75% for the registry vs 5 events,
0.69% for the IDE study).
Discussion
This interim report from the Micra TPS Post-Approval
Registry has demonstrated a high level (99.6%) of successful
implants with a low level (1.51%) of major complications. To
our knowledge, this represents the ﬁrst large-scale report of a
TPS in the post-approval setting. These data closely mirror
the ﬁndings of the Micra IDE study that demonstrated a
similarly high level (99.2%) of implant success with a low
level (2.89%) of major complications through 30 days.5
Given the novelty of the technology and implantation
technique, appropriate concern has been raised over the
consistency of the implant success and complication rates
as a wider adoption took place. However, results from this
early interim report demonstrate impressive consistency
with the results from the IDE study, even though 86.6% of
implanters were new and did not implant Micra prior to this
registry. Further, 77.3% of cases were successfully deployed
with 2 deployments.
The patient demographics are slightly different between
the groups, with the registry population having less conges-
tive heart failure, coronary artery disease, hypertension,
chronic obstructive pulmonary disease, and atrial ﬁbrillation,
but a higher percentage of patients had no venous access for a
transvenous pacemaker. The mean ejection fraction within
the registry group was lower, and there was a signiﬁcant
number of patients (13.1%) that had a previously implanted
cardiac implantable electronic device. Of note, 20.9% of
registry patients had a condition that precluded the use of a
transvenous pacemaker. The primary indication for pacing
in both studies was what would be considered a conventional
single-chamber indication for pacing with permanent atrial
ﬁbrillation, although the percentage was slightly higher in
the IDE study (64% vs 57.7%).
The outstanding electrical performance of Micra TPS has
also been maintained within the registry population, with a
97% implant threshold of,2 V, and 87.2% had a pacing cap-
ture threshold1 V, similar to what was reported for the IDE
study.6 The average impedance was 7216 181 U at implant,
and the mean R-wave amplitude was 11.4 6 5.3 mV.
Longer-term follow-up in the IDE study has shown a trend
to improvement of these parameters with time.
This registry has demonstrated a remarkably low level of
major complications, and particularly noticeable is the low
level of pericardial effusion and need for emergency cardiac
surgery. There were 5 pericardial effusion/perforation events
observed thus far in the registry population, only 1 of which
met the criteria for a major complication. This may be
reﬂective of the robust training program that is mandated
prior to implantation of Micra TPS. A focus on training has
been to implant the device on the septal aspect of the right
Table 3 Components of Major Complications for Post-Approval and Investigational Studies
Major Complication Criterion
30-Day Event Rate
Odds Ratio (Post-Approval vs
Investigational) (95% CI)
Post-Approval (n 5 795)
No. (Patients, %)
Investigational (n 5 726)
No. (Patients, %)
Total Major Complications 13 (12, 1.51%) 24 (21, 2.89%) 0.58 (0.27, 1.25)*
Death 1 (1, 0.13%) 1 (1, 0.14%) 0.91 (0.06–14.66)
Hospitalization 4 (4, 0.50%) 9 (8, 1.10%) 0.45 (0.14–1.51)
Prolonged hospitalization 9 (8, 1.01%) 16 (14, 1.93%) 0.52 (0.22–1.24)
System revision 2 (2, 0.25%) 3 (3, 0.41%) 0.61 (0.10–3.65)
Loss of device function 0 (0, 0%) 2 (2, 0.28%) NE
CI 5 conﬁdence interval; NE 5 not estimable.
*Adjusted analyses for baseline characteristics (P 5 0.16). Unadjusted results were similar (0.52, 95% CI: 0.25-1.05).
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ventricle, where it is perceived that the risk of perforation
might be lower compared with the risk in the true apex, which
may include the thin free wall of the right ventricle. More
patients had the Micra placed in a septal location in the
Post-Approval Registry compared those in the IDE study
(52% vs 33%). Additional focus has been placed on patient
risk factors for perforation. Of note, patients with cardiac
perforation/effusion events had at least 1 risk factor reported
to be associated with cardiac injury in transvenous
pacemaker implants.7–9
Consistent with all other leadless pacing data sets, there
was no infection requiring extraction of the Micra. We
suspect that the small size, lack of proximity to a cutaneous
incision, and late encapsulation will all positively inﬂuence
a reduced infection rate. Similarly, the rate of device
dislodgement remains low, with only 1 recorded case in the
registry cohort. Remarkably, across a combined 1521
patients from both the IDE and registry studies, this is the
only reported macrodislodgement to date, for a raw rate of
0.066%. Even in this case, no embolization occurred. Among
patients implanted with a transvenous pacemaker system in
the FOLLOWPACE study, lead dislodgement was reported
at a rate of 3.3% within 2 months of implant.2
The registry data mirror that of the IDE study, with a
vascular/groin related complication rate of 0.75% overall.
This is remarkably low when one takes into account that
the delivery system is inserted using a 23F introducer sheath.
Routine vascular ultrasound guidance for venous puncture
may further lower this risk.
Study limitations
Although the interim acute performance results of the registry
data are very reassuring regarding the efﬁcacy and safety of
the Micra TPS, there are some limitations to the data. The
registry was intended to include as many patients as possible
over as many centers and geographies as possible. However,
there may be some degree of bias in favor of the patients that
are approached to join a registry by the recruiting physician,
and whereas it is anticipated that this registry represents a
real-world population, the data do not include all patients
implanted with Micra TPS worldwide. Further, this report
is an interim analysis with limited follow-up, including
patients who had not yet been followed for 30 days, and it
reﬂects the geographies of enrolled patients who were
primarily from Europe. However, enrollment of patients in
the United States is continuing, and patients in the registry
will be followed for a minimum of 9 years. In addition,
few patients had follow-up electrical data available, and
thus battery projections are preliminary and based on only
54 patients.
Conclusions
Initial results from the Micra TPS Post-Approval Registry
have demonstrated a high level of implant success
along with excellent electrical performance in short-term
follow-up. Importantly, despite this therapy being available
more broadly post-approval, the level of major complications
remains low. This offers signiﬁcant reassurance for leadless
pacing as a therapy in moving forward but should not drive
complacency inmaintaining this high standard of clinical care.
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